ChemLifeIntel
CHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
ChemLifeIntel/Companies/University of Sydney

University of Sydney

HIGH RISKHQ: — · Private · Founded —
LISTINGPrivateFOUNDED0
FOCUS THERAPY AREAS
Manufacturer
COMPANY INTELLIGENCE SNAPSHOTlive
0
Manufacturing Sites
1
Intelligence Briefs
1
Active Regulatory Actions
HQ Country
NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ
View regulatory detail

INTELLIGENCE

Showing 1 of 1 briefs on University of Sydney
REGULATORY INTELLIGENCE·Regulatory Trend

University of Sydney Review Challenges Opioid Efficacy: Major Implications for Global Pharma Supply Chains

A landmark University of Sydney review reveals opioids often offer minimal, short-lived acute pain relief, performing no better than placebo for many conditions. This challenges established prescribing norms for molecules like codeine and oxycodone, necessitating immediate strategic re-evaluation for pharmaceutical manufacturers, procurement, and regulatory affairs globally, driving a critical shift towards non-opioid alternatives and revised clinical guidelines.

90-Day Activity
University of SydneyCodeineHSN 3004.40
RCRavi Chandrasekaran· Principal Intelligence Analyst
8d ago Regulatory Trend